If this is the narrative then Coumo should be on his way to President 2024 and Desantis should be facing criminal investigations
You can go take a look on my commentary about Cuomo in the threads about him. For a short summary, I stated multiple times it is absurd that his minor #MeToo transgressions took him down, he should actually be facing charges and shoved out of office for hiding the nursing home deaths. It shows people care much less about covering up hundreds of deaths over some minor sexual harassment -- sadly this shows what society appears to value these days.
I agree But that was the plan Cuomo was going out one way or another The left media choose to jump on metoo instead of the nursing home murders coverup because they did not want to give any Democrat responsibility for Covid failure
Pfizer agrees to let other companies make its COVID-19 pill https://apnews.com/article/coronavi...r-inc-health-d4b4d2f5d2e001cc3573526e680c07f8 Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population. In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population. The deal excludes some large countries that have suffered devastating coronavirus outbreaks. For example, while a Brazilian drug company could get a license to make the pill for export to other countries, the medicine could not be made generically for use in Brazil. Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere, could help to end the pandemic quicker. “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said. He estimated that other drugmakers would be able to start producing the pill within months, but acknowledged the agreement wouldn’t please everyone. “We try to strike a very delicate balance between the interests of the (company), the sustainability required by generic producers and most importantly, the public health needs in lower and middle-income countries,” Burrone said. Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency. Earlier this month, Pfizer said its pill cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections. Independent experts recommended halting the company’s study based on its promising results. Pfizer said it would ask the U.S. Food and Drug Administration and other regulators to authorize the pill as soon as possible, Since the pandemic erupted last year, researchers worldwide have raced to develop a pill to treat COVID-19 that can be taken at home easily to ease symptoms, speed recovery and keep people out of the hospital. At the moment, most COVID-19 treatments must be delivered intravenously or by injection. Britain authorized the Merck’s COVID-19 pill earlier this month, and it is pending approval elsewhere. In a similar deal with the Medicines Patent Pool announced in October, Merck agreed to let other drugmakers make its COVID-19 pill, molnupiravir, available in 105 poorer countries. Doctors Without Borders said it was “disheartened” that the Pfizer deal does not make the drug available to the entire world, noting that the agreement announced Tuesday also excludes countries including China, Argentina and Thailand. “The world knows by now that access to COVID-19 medical tools needs to be guaranteed for everyone, everywhere, if we really want to control this pandemic,” said Yuanqiong Hu, a senior legal policy adviser at Doctors Without Borders. The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes for wider production. A hub set up by the World Health Organization in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join. Fewer than 1% of Pfizer’s COVID-19 shots have gone to poorer countries.
U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for $5.3 bln https://www.reuters.com/business/he...ses-pfizers-covid-19-pill-529-bln-2021-11-18/ Nov 18 (Reuters) - Pfizer Inc (PFE.N) said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease. (More at above url)
US government plans to purchase large supply of COVID-19 treatment sotrovimab for winter surge First supplies expected to arrive December 17th, in time for potential winter surge https://www.foxnews.com/health/us-g...stantial-supply-covid-19-treatment-sotrovimab The United States government announced plans to purchase sotrovimab, an investigational monoclonal antibody used for the early treatment of COVID-19, according to a press release from the drugmakers, GlaxoSmithKline (GSK) plc and Vir Biotechnology, Inc. The contracts total approximately one billion dollars, according to the news release. "Given the large number of patients who continue to become ill with COVID-19 across many regions in the US, there is an ongoing need for access to effective treatments. We are proud to work with the US government to help make sotrovimab available for these patients.", Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said in a news release. Sotrovimab was granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in May 2021. Under the EUA, the investigational single-dose intravenous infusion SARS-CoV-2 monoclonal antibody can be used to treat mild-to-moderate COVID-19 in adults and children 12 years of age and older, who tested positive for COVID-19, and are at high risk for developing severe cases of COVID-19 leading to hospitalization or death, according to the FDA website. "It gives patients a real heads start in fighting off the virus," Bart Murray, Vice President of COVID Therapeutics at GSK told Fox news in an interview. Murray told Fox news that patients who test positive for Covid-19 need to be aware of this treatment and should ask their doctors if it is appropriate for them, especially if they have an underlying condition or are immunocompromised. "People need to know there are highly effective treatments for patients at high risk – and shouldn’t hesitate to ask their doctor to get treated," Murray told Fox. Sotrovimab is not authorized for use in every case. According to the FDA website, sotrovimab is not authorized for those hospitalized due to COVID-19, or require oxygen therapy due to COVID-19. It is also not indicated in patients who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity), the health agency stated on the website. The FDA also says SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when given to patients hospitalized with COVID-19 requiring high flow oxygen or mechanical ventilation. Final data released from the COMET-ICE Phase III trial involving 1057 participants , showed sotrovimab reduced hospitalization and risk of death by 79 percent in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease at day 29 compared to placebo, according to a news release by the companies. The release noted that in vitro data suggested sotrovimab maintains activity against the Delta variant and other variants being monitored. The companies also announced that data from the COMET-Tail Phase III study suggested that injecting Sotrovimab into the patient’s muscle was similarly effective compared to administering it intravenously in high-risk populations. Barron said this potentially offers a more convenient option for patients suffering from Covid-19, according to the release. GSK officials told Fox News they will supply these doses to the US government by December 17, 2021, expanding nationwide access to sotrovimab for patients. "With the expected winter surge months ahead of us, the supply is timely", Murray told Fox news interview. Murray explained during the interview that the treatment is free for those who are eligible for the therapy, thanks to the government contract. "It’s important to get the vaccine – but if you still get the virus you still have the option to get the antibodies at no cost."
GOP fights COVID mandates, then blames Biden as cases rise https://www.seattletimes.com/nation...vid-mandates-then-blames-biden-as-cases-rise/